Dendritic cell–derived exosomes for cancer therapy

作者：Jonathan M. Pitt, Fabrice André, Sebastián Amigorena, Jean‐Charles Soria, Alexander Eggermont, Guido Kroemer, Laurence Zitvogel · 发表于：Journal of Clinical Investigation · 年份：2016 · DOI：10.1172/jci81137 · 被引用次数：625 · 研究领域：Extracellular vesicles in disease、Immunotherapy and Immune Responses、Immune Cell Function and Interaction

DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.